E A Idelevich1, K Becker2. 1. Institute of Medical Microbiology, University Hospital Münster, Münster, Germany. Electronic address: evgeny.idelevich@ukmuenster.de. 2. Institute of Medical Microbiology, University Hospital Münster, Münster, Germany.
Abstract
BACKGROUND: Antimicrobial susceptibility testing (AST) results are crucial for timely administration of effective antimicrobial treatment, and, thus, should be made available to clinicians as fast as possible. In particular, increasing rates of multidrug-resistant organisms emphasize the need for rapid AST (rAST). OBJECTIVES: This article aims to provide microbiologists and clinicians with a critical overview of the current state of possibilities to accelerate AST. We also intend to discuss technical and strategic aspects of rAST, which may be helpful to academic researchers and assay developers in the industry. SOURCES: We have reviewed literature on rAST methods and their implementation in routine diagnostics. CONTENT: Phenotypic rAST is universal, mechanism-independent and allows exact categorization, but it demands time for the microorganisms to start the growth and to express the response to antibiotics. Detection of selected resistance mechanisms is more rapid, but the interpretation of its clinical impact is limited. Technical challenges of phenotypic rAST include inoculum effect, delayed expression of resistance, lag phase and initial biomass increase in susceptible isolates. Criteria for a successful rAST assay are ease of use, random access, capacity for simultaneous testing of multiple specimens, affordability and financial attractiveness for industry. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)-based AST seems to be particularly promising, as it can optimally be combined with MALDI-TOF MS identification. Direct testing from clinical specimens provides particularly early findings, with positive blood cultures being the most suitable specimen type. Polymicrobial samples and inoculum effect are serious obstacles for direct AST from other clinical specimens. Next to the technology improvement, optimization of pre-analytics and laboratory organization is essential. IMPLICATIONS: It appears feasible to generate an AST report within the same working shift; however, only affordable and easy-to-use rAST technologies have a chance to enter broad diagnostic routine. Efforts should be made by industry, authorities and academia to enable wide dissemination of rAST in clinical diagnostics.
BACKGROUND: Antimicrobial susceptibility testing (AST) results are crucial for timely administration of effective antimicrobial treatment, and, thus, should be made available to clinicians as fast as possible. In particular, increasing rates of multidrug-resistant organisms emphasize the need for rapid AST (rAST). OBJECTIVES: This article aims to provide microbiologists and clinicians with a critical overview of the current state of possibilities to accelerate AST. We also intend to discuss technical and strategic aspects of rAST, which may be helpful to academic researchers and assay developers in the industry. SOURCES: We have reviewed literature on rAST methods and their implementation in routine diagnostics. CONTENT: Phenotypic rAST is universal, mechanism-independent and allows exact categorization, but it demands time for the microorganisms to start the growth and to express the response to antibiotics. Detection of selected resistance mechanisms is more rapid, but the interpretation of its clinical impact is limited. Technical challenges of phenotypic rAST include inoculum effect, delayed expression of resistance, lag phase and initial biomass increase in susceptible isolates. Criteria for a successful rAST assay are ease of use, random access, capacity for simultaneous testing of multiple specimens, affordability and financial attractiveness for industry. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)-based AST seems to be particularly promising, as it can optimally be combined with MALDI-TOF MS identification. Direct testing from clinical specimens provides particularly early findings, with positive blood cultures being the most suitable specimen type. Polymicrobial samples and inoculum effect are serious obstacles for direct AST from other clinical specimens. Next to the technology improvement, optimization of pre-analytics and laboratory organization is essential. IMPLICATIONS: It appears feasible to generate an AST report within the same working shift; however, only affordable and easy-to-use rAST technologies have a chance to enter broad diagnostic routine. Efforts should be made by industry, authorities and academia to enable wide dissemination of rAST in clinical diagnostics.
Authors: Hanna Hakvoort; Evelyn Bovenkamp; Kerryl E Greenwood-Quaintance; Suzannah M Schmidt-Malan; Jay N Mandrekar; Audrey N Schuetz; Robin Patel Journal: J Clin Microbiol Date: 2020-09-22 Impact factor: 5.948
Authors: David Baunoch; Natalie Luke; Dakun Wang; Annah Vollstedt; Xinhua Zhao; Dicken S C Ko; Shuguang Huang; Patrick Cacdac; Larry T Sirls Journal: Infect Drug Resist Date: 2021-08-19 Impact factor: 4.003
Authors: Evan A Larson; Josiah J Rensner; Kristina R Larsen; Bryan Bellaire; Young Jin Lee Journal: J Am Soc Mass Spectrom Date: 2022-05-27 Impact factor: 3.262
Authors: Alex van Belkum; Carey-Ann D Burnham; John W A Rossen; Frederic Mallard; Olivier Rochas; William Michael Dunne Journal: Nat Rev Microbiol Date: 2020-02-13 Impact factor: 60.633
Authors: Kristel C Tjandra; Nikhil Ram-Mohan; Ryuichiro Abe; Marjan M Hashemi; Jyong-Huei Lee; Siew Mei Chin; Manuel A Roshardt; Joseph C Liao; Pak Kin Wong; Samuel Yang Journal: Antibiotics (Basel) Date: 2022-04-12
Authors: Benjamin Berinson; Anna Both; Laura Berneking; Martin Christner; Marc Lütgehetmann; Martin Aepfelbacher; Holger Rohde Journal: J Clin Microbiol Date: 2021-07-19 Impact factor: 5.948